Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Although not yet approved for type 1 diabetes, GLP-1 agonists have been tested in multiple trials involving people with the condition
The most common side effects include the following: Tirzepatide is a medication originally developed to manage blood sugar levels in people with type 2 diabetes, but it has shown significant weight loss effects
In addition to their metabolic actions, GLP-1 receptor agonists modulate neural pathways involved in appetite regulation
Some patients and providers explore intermittent approaches or dose adjustments after achieving goal weight, though limited evidence supports these strategies with tirzepatide specifically
Together, they can support steady weight loss without extreme restriction
)
